Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia

Molecular Pharmacology

Volumn 85, Issue 6, 2014, Pages 866-876

  Wu, Minghui ^a   Wang, Xue ^a   McGregor, Natalie ^b   Pienta, Kenneth J ^b   Zhang, Jingsong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIRTECAN; IRINOTECAN; PROTEIN P53; RAD51 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F4; VELIPARIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR VOLUME; UPREGULATION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BENZIMIDAZOLES; CAMPTOTHECIN; CELL HYPOXIA; CELL LINE, TUMOR; DNA DAMAGE; DNA PRIMERS; DNA, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RAD51 RECOMBINASE; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84899529172     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.090688     Document Type: Article

References (33)

1. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, and Ryan C et al. (2013) Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19:3621-3630.
2. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, and Stransky N et al. (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44:685-689.
3. Bindra RS and Glazer PM (2007) Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 26:2048-2057.
4. Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, and Glazer PM (2004) Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 24:8504-8518.
5. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, and Yu J et al. (2011) Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19:664-678.
6. Bristow RG and Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180-192.
7. Brown ET and Holt JT (2009) Rad51 overexpression rescues radiation resistance in BRCA2-defective cancer cells. Mol Carcinog 48:105-109.
8. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, and Helleday T et al. (2010) Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 70:8045-8054.
9. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, and O'Connor MJ et al. (2009) Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134.
10. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, and Brenner JC et al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-243.
11. Helleday T (2010) Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31:955-960.
12. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, and Marchionni L et al. (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE 5:e11208.
13. Klein HL (2008) The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 7:686-693.
14. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, and Murgo AJ et al. (2011) Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 71:5626-5634.
15. Lee SA, Roques C, Magwood AC, Masson JY, and Baker MD (2009) Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression. DNA Repair (Amst) 8:170-181.
16. Liu JJ and Zhang J (2013) Sequencing systemic therapies in metastatic castrationresistant prostate cancer. Cancer Control 20:181-187.
17. Lo Russo P, Ji JJ, Li J, Heilbrun LK, Shapiro G, Sausville EA, Boerner SA, Smith DW, Pilat MJ, and Zhang J et al. (2011) Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors (Abstract). J Clin Oncol 29(Suppl):3000.
18. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, and Bishop DK (2007) RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 67:9658-9665.
19. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, and Ashworth A (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1:315-322.
20. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, and Bristow RG (2005) Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 76:168-176.
21. Moynahan ME and Jasin M (2010) Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 11:196-207.
22. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher BA, Doroshow JH, and Pommier Y (2014) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13:433-443.
23. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, and Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588-5599.
24. Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, and Kaufmann SH (2012) Enhanced killing of cancer cells by poly (ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem 287:4198-4210.
25. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, and Omlin A et al. (2013) The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14:882-892.
26. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, and Livingston DM (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88:265-275.
27. Seruga B, Ocana A, and Tannock IF (2011) Drug resistance in metastatic castrationresistant prostate cancer. Nat Rev Clin Oncol 8:12-23.
28. Smith LM, Willmore E, Austin CA, and Curtin NJ (2005) The novel poly (ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res 11:8449-8457.
29. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, and Schmutzler RK et al. (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244.
30. Yang Z, Waldman AS, and Wyatt MD (2012) Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol 83:741-746.
31. Yap TA, Sandhu SK, Carden CP, and De Bono JS (2011) Poly (ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61:31-49.
32. Zhang J, Hu S, Schofield DE, Sorensen PH, and Triche TJ (2004) Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res 64:6026-6034.
33. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, and Pommier Y (2011) Poly (ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res 39:3607-3620.